Status:
COMPLETED
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
Eligibility Criteria
Inclusion
- Written informed consent
- Successful completion of study protocol 3104001
- Response or stable disease in study 3104001 at week 12
Exclusion
- New serious concurrent medical condition
- Not able to swallow the study drug
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT01429064
Start Date
June 1 2011
End Date
November 1 2015
Last Update
February 20 2017
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
The Urology Center of Colorado
Wheat Ridge, Colorado, United States, 80211
2
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut, United States, 06360
3
Cleveland Clinic
Cleveland, Ohio, United States, 44195
4
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States, 29572